Some of the predisposing factors that have been identified include: dose and duration of treatment, low CD4 count, advanced age and low body weight, co-prescription of didanosine or boosted protease inhibitor, pre-existing chronic kidney disease (CKD) and associated diabetes mellitus [8–10]. Here, CD4 is linked to diabetes mellitus.